Multi-Omics Analysis and Molecular Subtypes Provide Potential Therapeutic Implications in Fumarate Hydratase-deficient Renal Cell Carcinoma
RNA-seq (gene expression) · human · 93 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Kidney cancerThis series is part of our curated briefing on it.
- Samples
- 93 samples: 93 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE273036_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1135765 and SRA study SRP520602. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 56 samples read as cases, 37 as controls.
How we read this: Read from 93 sample titles: 93 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8417256 FHRCC01, primary tumor
- GSM8417257 FHRCC02, adjacent normal kidney tissue
- GSM8417258 FHRCC02, primary tumor
- GSM8417259 FHRCC03, primary tumor
- GSM8417260 FHRCC04, adjacent normal kidney tissue
- GSM8417261 FHRCC04, primary tumor
- GSM8417262 FHRCC05, primary tumor
- GSM8417263 FHRCC06, adjacent normal kidney tissue
- GSM8417264 FHRCC06, primary tumor
- GSM8417265 FHRCC07, primary tumor
- GSM8417266 FHRCC08, adjacent normal kidney tissue
- GSM8417267 FHRCC08, primary tumor
- GSM8417268 FHRCC09, adjacent normal kidney tissue
- GSM8417269 FHRCC09, primary tumor
- GSM8417270 FHRCC15, adjacent normal kidney tissue
- GSM8417271 FHRCC15, primary tumor
- GSM8417272 FHRCC16, adjacent normal kidney tissue
- GSM8417273 FHRCC16, primary tumor
- GSM8417274 FHRCC19, primary tumor
- GSM8417275 FHRCC23, adjacent normal kidney tissue
- GSM8417276 FHRCC23, primary tumor
- GSM8417277 FHRCC26, adjacent normal kidney tissue
- GSM8417278 FHRCC26, primary tumor
- GSM8417279 FHRCC27, adjacent normal kidney tissue
- GSM8417280 FHRCC27, primary tumor
- GSM8417281 FHRCC28, adjacent normal kidney tissue
- GSM8417282 FHRCC28, primary tumor
- GSM8417283 FHRCC29, primary tumor
- GSM8417284 FHRCC30, adjacent normal kidney tissue
- GSM8417285 FHRCC30, primary tumor
- GSM8417286 FHRCC32, primary tumor
- GSM8417287 FHRCC35, adjacent normal kidney tissue
- GSM8417288 FHRCC35, primary tumor
- GSM8417289 FHRCC38, adjacent normal kidney tissue
- GSM8417290 FHRCC38, primary tumor
- GSM8417291 FHRCC39, adjacent normal kidney tissue
- GSM8417292 FHRCC39, primary tumor
- GSM8417293 FHRCC42, adjacent normal kidney tissue
- GSM8417294 FHRCC42, primary tumor
- GSM8417295 FHRCC43, primary tumor
+ 53 more — browse all 93 samples with per-sample file links →
- GSE216494 Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro 12 samples same disease briefing · shares therapeutic
- GSE216495 Nonclinical in-vitro evaluation of the transcriptomic and metabolic effects of immune checkpoint inhibitors on sunitinib-resistant renal cell carcinoma 36 samples same disease briefing
- GSE214635 The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis 18 samples same disease briefing
- GSE174740 Drug repurposing identifies a synergistic high-order drug combination to treat sunitinib-resistant renal cell carcinoma 11 samples same disease briefing
- GSE223688 SETD2 loss sensitizes kidney cancer cells to DNA hypomethylating agents 6 samples same disease briefing
- GSE193006 Transcriptome RNA sequencing data of sarcomatoid renal cell carcinoma cell line SRCC and its subclones with different phenotypes. 5 samples same disease briefing
- GSE17895 Somatic Mutation Screen of Clear Cell RCC 160 samples same disease briefing
- GSE15641 Gene signatures of progression and metastasis in renal cell cancer 92 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.